Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY

Indaptus Therapeutics, Inc.

2024-Q1 EPS reported -$0.45

R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.
Initiated multi-dose cohort in Phase 1 trial of Decoy20 after positive preliminary results from second cohort.
Granted key patent in January 2024 to expand intellectual property portfolio.
Accepted for poster presentation at ASCO Annual Meeting on June 1, 2024, highlighting initial Phase 1 Decoy20 data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Indaptus Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.